Key result
Hairpin ribozymes identified by combinatorial screening inhibited HBV replication in transfected human hepatocellular carcinoma cells by up to 80%.
Combinatorial screening identified catalytically active hairpin ribozymes that effectively inhibit intracellular HBV replication in human hepatocellular carcinoma cells.
May support ribozyme antivirals for HBV; leaves open in vivo and clinical validation.
A combinatorial screening method has been used to identify hairpin ribozymes that inhibit hepatitis B virus (HBV) replication in transfected human hepatocellular carcinoma (HCC) cells. A hairpin ribozyme library (5 x 10(5) variants) containing a randomized substrate-binding domain was used to identify accessible target sites within 3.3 kb of full-length in vitro-transcribed HBV pregenomic RNA. Forty potential target sites were found within the HBV pregenomic RNA, and 17 sites conserved in all four subtypes of HBV were chosen for intracellular inhibition experiments. Polymerase II and III promoter expression constructs for corresponding hairpin ribozymes were generated and cotransfected into HCC cells together with a replication-competent dimer of HBV DNA. Four ribozymes inhibited HBV replication by 80, 69, 66, and 49%, respectively, while catalytically inactive mutant forms of these ribozymes affected HBV replication by 36, 28, 0, and 0%. These findings indicate that the inhibitory effects on HBV replication were largely mediated by the catalytic activity of the ribozymes. In conclusion, we have identified catalytically active RNAs by combinatorial screening that mediate intracellular antiviral effects on HBV.
No takes yet. Share an insight, caveat, or question.
Putlitz et al. (1999) studied Hepatitis B Virus. Hairpin ribozymes vs. Catalytically inactive mutant ribozymes was evaluated on Inhibition of HBV replication. Hairpin ribozymes identified by combinatorial screening inhibited HBV replication in transfected human hepatocellular carcinoma cells by up to 80%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: